Transgenic expression of an expanded (GCG)13 repeat PABPN1 leads to weakness and coordination defects in mice, Neurobiol. Dis, vol.18, pp.528-536, 2005. ,
PABP2 polyalanine tract expansion causes intranuclear inclusions in oculopharyngeal muscular dystrophy, Ann. Neurol, vol.48, pp.798-802, 2000. ,
Nuclear inclusions in oculopharyngeal dystrophy, Acta Neuropathol, vol.49, pp.85-87, 1980. ,
Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy, Nat. Genet, vol.18, pp.164-167, 1998. ,
The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13, Hum. Mol. Genet, vol.4, pp.429-434, 1995. ,
Current targeted therapeutic strategies for oculopharyngeal muscular dystrophy: from pharmacological to RNA replacement and gene editing therapies, Int. J. Clin. Neurosci. Ment. Health, vol.3, p.6, 2016. ,
Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy, Hum. Mol. Genet, vol.12, pp.2609-2623, 2003. ,
Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1, Hum. Mol. Genet, vol.17, pp.2108-2117, 2008. ,
Valproic acid is protective in cellular and worm models of oculopharyngeal muscular dystrophy, Neurology, vol.91, pp.551-561, 2018. ,
Lithium chloride attenuates cell death in oculopharyngeal muscular dystrophy by perturbing Wnt/b-catenin pathway, 2013. ,
Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death, Hum. Mol. Genet, vol.10, pp.2341-2351, 2001. ,
Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy, Traffic, vol.6, pp.766-779, 2005. ,
Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells, Hum. Mol. Genet, vol.14, pp.3673-3684, 2005. ,
Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo, Hum. Mol. Genet, vol.18, pp.1849-1859, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00399030
Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody, Hum. Mol. Genet, vol.15, pp.105-111, 2006. ,
Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy, Sci. Transl. Med, vol.2, pp.34-40, 2010. ,
Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy, Hum. Mol. Genet, vol.15, pp.23-31, 2006. ,
Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice, Nat. Med, vol.11, pp.672-677, 2005. ,
Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I/IIa clinical study, Mol. Ther, vol.22, pp.219-225, 2014. ,
PABPN1 gene therapy for oculopharyngeal muscular dystrophy, Nat. Commun, vol.8, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01959996
, , 2002.
yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy, J. Biol. Chem, vol.277, pp.12263-12269 ,
Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy, EMBO Mol. Med, vol.3, pp.35-49, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00575087
Intravenous Trehalose Improves Dysphagia and Muscle Function in Oculopharyngeal Muscular Dystrophy (OPMD): Preliminary Results of 24 Weeks Open Label Phase 2 Trial (S28.004), Neurology, vol.86, 2016. ,
Antisense inhibition: oligonucleotides, ribozymes, and siRNAs, Methods Mol. Med, vol.106, pp.11-34, 2005. ,
Synthetic hammerhead ribozymes as therapeutic tools to control disease genes, Curr. Gene Ther, vol.5, pp.11-24, 2005. ,
Structure-based mechanistic insights into catalysis by small self-cleaving ribozymes, Curr. Opin. Chem. Biol, vol.41, pp.71-83, 2017. ,
MicroRNA: Biogenesis, Function and Role in Cancer, Curr. Genomics, vol.11, pp.537-561, 2010. ,
MicroRNAs: miRRORS of health and disease, Transl. Res, vol.157, pp.157-162, 2011. ,
MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, vol.116, pp.281-297, 2004. ,
Towards a molecular understanding of microRNA-mediated gene silencing, Nat. Rev. Genet, vol.16, pp.421-433, 2015. ,
Automated design of hammerhead ribozymes and validation by targeting the PABPN1 gene transcript, Nucleic Acids Res, vol.44, p.39, 2016. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01351212
, , 2000.
, Oculopharyngeal MD among Bukhara Jews is due to a founder (GCG)9 mutation in the PABP2 gene, Neurology, vol.55, pp.1267-1270
GCG)11 founder mutation in the PABPN1 gene of OPMD Uruguayan families, Neuromuscul. Disord, vol.15, pp.185-190, 2005. ,
Two different PABPN1 expanded alleles in a Mexican population with oculopharyngeal muscular dystrophy arising from independent founder effects, Br. J. Ophthalmol, vol.92, pp.998-1002, 2008. ,
, Genetika, vol.52, pp.376-384, 2016.
Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo, Mol. Ther, vol.17, pp.169-175, 2009. ,
Wild-type PABPN1 is antiapoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation, Hum. Mol. Genet, vol.17, pp.1097-1108, 2008. ,
Mammalian poly(A)-binding protein II. Physical properties and binding to polynucleotides, J. Biol. Chem, vol.268, pp.2937-2945, 1993. ,
Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy, Neurobiol. Dis, vol.26, pp.546-557, 2007. ,
Immunodetection of poly(A) binding protein II in the cell nucleus, Exp. Cell Res, vol.214, pp.75-82, 1994. ,
RNA therapeutics: beyond RNA interference and antisense oligonucleotides, Nat. Rev. Drug Discov, vol.11, pp.125-140, 2012. ,
DOI : 10.1038/nrd3625
URL : http://europepmc.org/articles/pmc4743652?pdf=render
Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins, Proc. Natl. Acad. Sci. USA, vol.108, pp.14258-14263, 2011. ,
Ribozymes as therapeutic tools for genetic disease, Hum. Mol. Genet, vol.7, pp.1649-1653, 1998. ,
DOI : 10.1093/hmg/7.10.1649
URL : https://academic.oup.com/hmg/article-pdf/7/10/1649/1784596/7-10-1649.pdf
Identifying proteins that bind to specific RNAs -focus on simple repeat expansion diseases, Nucleic Acids Res, vol.44, pp.9050-9070, 2016. ,
Modeling simple repeat expansion diseases with iPSC technology, Cell. Mol. Life Sci, vol.73, pp.4085-4100, 2016. ,
DOI : 10.1007/s00018-016-2284-0
, , 2013.
, Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease, Mol. Ther, vol.21, pp.1898-1908
Maintenance of C. elegans, pp.1-11, 2006. ,
C. elegans SIR-2.1 interacts with 14-3-3 proteins to activate DAF-16 and extend life span, Cell, vol.125, pp.1165-1177, 2006. ,